Linaclotide Research Dosage: Published Protocol Reference
Linaclotide dosage references vary by route and study context. The database lists Oral: 290 mcg, Once daily, Oral: 145 mcg, Once daily, and Oral: 72 mcg, Once daily. These are research-context references, not a universal protocol.
Direct Answer
Linaclotide (Linzess) is FDA-approved for IBS-C and chronic idiopathic constipation, with robust Phase 3 data across multiple trials. It is one of the most prescribed GI peptide drugs in the US, with real-world data supporting its Phase 3 results. For guanylate cyclase-C agonism and IBS-C research, linaclotide is the established reference compound.
- Evidence grade
- Level A
- Research status
- FDA Approved
- Category
- Healing & Recovery
- Best for
- IBS-C, chronic idiopathic constipation, guanylate cyclase-C agonism, visceral pain modulation
Research Dosage References
- <strong>Oral</strong> - 290 mcg - Once daily - FDA-approved dose for IBS-C. Take on empty stomach at least 30 minutes before first meal of the day.
- <strong>Oral</strong> - 145 mcg - Once daily - FDA-approved dose for CIC. Can be reduced to 72 mcg if 145 mcg is not tolerated.
- <strong>Oral</strong> - 72 mcg - Once daily - Lower dose approved for CIC. May be preferred in patients sensitive to diarrhea.
Half-Life
Minimal systemic absorption (acts locally in GI tract; active metabolite MM-419447 has local GI activity).
Evidence Limits
Dosage entries are compiled from labels, published studies, and research-context references where available. For Linaclotide, the evidence grade is Level A, and the current research status is FDA Approved.
Safety Signals
- Contraindicated in children under 2 years (risk of serious dehydration and death in neonatal mice)
- Avoid in patients 2 to less than 18 years old
- Contraindicated in known or suspected mechanical GI obstruction
- Discontinue if severe diarrhea develops
- Take on empty stomach for optimal absorption
Evidence Snapshot
| Evidence grade | Level A |
|---|---|
| Research status | FDA Approved |
| Best supported outcomes | IBS-C Symptom Relief (Level A), Chronic Idiopathic Constipation Relief (Level A), Visceral Pain Reduction (Level A), and Diarrhea (Adverse) (Level A) |
| Primary citation count | 3 |
| Last reviewed | 2026-04-04 |
Related Guides
How to Cite This Page
ExaminePeptides. "Linaclotide Research Dosage: Published Protocol Reference." Last reviewed 2026-04-04. https://examinepeptides.com/answers/linaclotide-research-dosage/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.